Skip to content

Renal Allograft : Evaluation of Parenchymal Fibrosis by Elastography

Evaluation of the Potential of Elastography for Noninvasive Assessment of Fibrosis in Kidney Transplant

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01234363
Acronym
GREFE
Enrollment
60
Registered
2010-11-04
Start date
2010-05-31
Completion date
2013-09-30
Last updated
2013-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplant

Keywords

Renal allograft, kidney, fibrosis, elastography, elasticity

Brief summary

The purpose of this study is to assess the potential of elastography for noninvasive assessment of fibrosis in renal allograft.

Interventions

DEVICEMagnetic Resonance Elastography, and Supersonic Shear Imaging

Magnetic Resonance Elastography, and Supersonic Shear Imaging

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Renal allograft performed less than 3 months before enrolment

Exclusion criteria

* Contra-indication to magnetic resonance imaging * Contra-indication to biopsy

Design outcomes

Primary

MeasureTime frame
Correlation between elasticity (as measured by elastography) and (a) Banff score for fibrosis, (b) glomerular filtration rate assessed by creatinine clearance, (c) glomerular filtration rate assessed by insulin clearance3 months and 12 months after graft

Secondary

MeasureTime frame
Number of technical failures12 months
Tolerance (assessed by a questionnaire)3 months and 12 months after graft
Evolution of the elasticity of the transplant between 3 and 12 months after graft3 months and 12 months after graft
Correlation between elasticity and arterial resistance index3 months and 12 months after graft

Countries

France

Contacts

Primary ContactROUVIERE Olivier, Pr
olivier.rouviere@netcourrier.com472 11 09 51

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026